Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000224493 refers to a sequence annotated as a “pseudogene similar to part of nucleostemin.” Pseudogenes are genomic sequences that closely resemble functional genes but are incapable of encoding functional proteins, typically due to disabling mutations or absence of regulatory elements[2][4]. The parental gene, nucleostemin (GNL3), is involved in cell cycle regulation and is a marker of stem and cancer cells[7]. While some pseudogenes exert regulatory effects on their parental genes (such as through noncoding RNA products), there is no experimentally validated function or disease association for this particular pseudogene[1][3][6][5][8]. It is not considered a therapeutic target, nor does it encode a receptor, enzyme, transporter, or similar druggable protein. Pseudogene annotations like this one may have research relevance, especially for studies of noncoding RNAs or regulatory genomics, but they currently lack direct clinical or translational significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudogene similar to part of nucleostemin.